Unknown PHASE2 INTERVENTIONAL 1-arm NCT02324803

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in Metastatic Renal Cell Carcinoma (mRCC) Patients

Sponsor: Southern China Urology Cancer Consortium

Conditions Adverse Drug Event Carcinoma, Renal Cell Self Efficacy

Interventions pazopanib

Updated 5 times since 2017 Last updated: Dec 18, 2014 Started: Jul 31, 2014 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Adverse Drug Event and Carcinoma, Renal Cell, this trial is ongoing. The trial is conducted by Southern China Urology Cancer Consortium and has accumulated 5 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Southern China Urology Cancer Consortium

Data source: Southern China Urology Cancer Consortium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China